Literature DB >> 11790855

Investigation on cell proliferation with a new antibody against thymidine kinase 1.

N Wang1, Q He, S Skog, S Eriksson, B Tribukait.   

Abstract

The cytosolic thymidine kinase 1 (TK1) is one of the enzymes involved in DNA replication. Based on biochemical studies, TK1 is activated at late G1 of cell cycle, and its activity correlates with the cell proliferation. We have developed a polyclonal anti-TK1 antibody against a synthetic peptide from the C-terminus of human TK1. Using this antibody, here we demonstrate the exclusive location of TK1 in the cytoplasm of cells. Cell cycle dependent TK1 expression was studied by simultaneous fluorescence staining for TK1 and bromodeoxyuridine, by using elutriated cells, and by quantitation of the amount TK1 in relation to the cellular DNA content. TK1, which was strongly expressed in the cells in S+G2 period, raised at late G1 and decreased during mitosis. The amount of TK1 increased three folds from late G1 to G2. TK1 positive cells were demonstrated in areas of proliferation activity of various normal and malignant tissues. The new anti-TK1 antibody works in archival specimens and is a specific marker of cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11790855      PMCID: PMC4618205          DOI: 10.1155/2001/658312

Source DB:  PubMed          Journal:  Anal Cell Pathol        ISSN: 0921-8912            Impact factor:   2.916


  10 in total

1.  XPA-210: a new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrence.

Authors:  Stefan Aufderklamm; Jörg Hennenlotter; Tilman Todenhoefer; Georgios Gakis; David Schilling; Ulrich Vogel; Ursula Kuehs; Johannes Dlugosch; Judith Knapp; Axel Merseburger; Valentina Gerber; Anna Ordelheide; Joachim Hevler; Arnulf Stenzl; Christian Schwentner
Journal:  World J Urol       Date:  2011-10-04       Impact factor: 4.226

2.  Erbb2 regulates inflammation and proliferation in the skin after ultraviolet irradiation.

Authors:  Justin G Madson; David T Lynch; Kelsey L Tinkum; Sumanth K Putta; Laura A Hansen
Journal:  Am J Pathol       Date:  2006-10       Impact factor: 4.307

3.  3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response.

Authors:  Matthias R Benz; Johannes Czernin; Martin S Allen-Auerbach; Sarah M Dry; Piriya Sutthiruangwong; Claudio Spick; Caius Radu; Wolfgang A Weber; William D Tap; Fritz C Eilber
Journal:  Cancer       Date:  2011-10-21       Impact factor: 6.860

4.  Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts.

Authors:  David M Atkinson; Michelle J Clarke; Ann C Mladek; Brett L Carlson; David P Trump; Mark S Jacobson; Brad J Kemp; Val J Lowe; Jann N Sarkaria
Journal:  Head Neck       Date:  2008-06       Impact factor: 3.147

5.  Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET.

Authors:  Lars Stelter; Simon Fuchs; Achim A Jungbluth; Gerd Ritter; Valerie A Longo; Pat Zanzonico; Nathanael Raschzok; Igor M Sauer; John S Bomalaski; Steven M Larson
Journal:  Mol Imaging Biol       Date:  2013-12       Impact factor: 3.488

6.  Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2.

Authors:  Omid S Tehrani; Kirk A Douglas; Jawana M Lawhorn-Crews; Anthony F Shields
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02-12       Impact factor: 9.236

Review 7.  Measuring proliferation in breast cancer: practicalities and applications.

Authors:  Mark J Beresford; George D Wilson; Andreas Makris
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

8.  A New Sandwich ELISA for Quantification of Thymidine Kinase 1 Protein Levels in Sera from Dogs with Different Malignancies Can Aid in Disease Management.

Authors:  Kiran Kumar Jagarlamudi; Laura Moreau; Sara Westberg; Henrik Rönnberg; Staffan Eriksson
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

9.  Assessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression.

Authors:  Songji Zhao; Yuji Kuge; Yan Zhao; Satoshi Takeuchi; Kenji Hirata; Toshiki Takei; Tohru Shiga; Hirotoshi Dosaka-Akita; Nagara Tamaki
Journal:  BMC Cancer       Date:  2013-11-06       Impact factor: 4.430

10.  18F-FLT Positron Emission Tomography (PET) is a Pharmacodynamic Marker for EWS-FLI1 Activity and Ewing Sarcoma.

Authors:  Christy L Osgood; Mohammed N Tantawy; Nichole Maloney; Zachary B Madaj; Anderson Peck; Elissa Boguslawski; Jennifer Jess; Jason Buck; Mary E Winn; H Charles Manning; Patrick J Grohar
Journal:  Sci Rep       Date:  2016-09-27       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.